top of page
Personalized Vaccine for Cancer Patients
Every cancer and every patient is unique. By analyzing genomics- and transcriptomics data, we design tumor-targeted peptide vaccines that could induce patient specific immune responses.
Tumor Analysis
Enhancing the immune response is crucial for every cancer patient. According to the World Health Organization, about 1 in 5 people will develop cancer at some point in their lives. Despite this, there are currently no personalized vaccines available to specifically boost the immune response against an individual's tumor.
Immune Topology
Our immune system's ability to fight diseases, including cancer, is influenced by HLA genes we inherit from our parents. These genes ensure the diversity of immune responses among individuals, which is crucial for human survival. HLAs act as messengers showing the immune system the tumor cells should be destroyed. Our unique technology considers all these inherited HLA genes when developing personalized vaccines.
Vaccine Design
Once we identify tumor-specific targets and patient-specific HLA profiles, our algorithm models the immune responses capable of recognizing and eliminating tumor cells. Based on this data, the software selects a set of vaccine peptides and ranks them by specificity and predicted efficacy. All the selected vaccine peptides are likely to induce tumor-targeted immune responses and undergo testing for safety and quality.
Relevant Publications
VERDI's personalized vaccine development technology is grounded in state-of-the-art science. We provide the most relevant publications. Please note that, like all modern technologies, our vaccine development process is not static; it is continuously improved as new data become available.
bottom of page